Drawing for BRONSON VITAMINS

USPTO serial 87818849

BRONSON VITAMINS

Reviewed by CopyMark Law Group

Reg. 5584958Status 702Registered
Filing date
Status date
Registration date
Oct 16, 2018
Examiner
GANDARA, KEYLA MARIA
Law office
TMO LAW OFFICE 117

What this means

Status 702 means the registration is active, Section 8 was accepted, and a Section 15 declaration of incontestability was also accepted. Incontestability strengthens your rights by limiting certain challenges after five years of continuous use. Continue use in commerce and plan for the 10-year Section 8 and 9 renewal.

Status 702: Status 702 means the registration is active, Section 8 was accepted, and a Section 15 declaration of incontestability was also accepted. Incontestability strengthens your rights by limiting certain challenges after five years of continuous use.

Need help with BRONSON VITAMINS?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Leo G. Lenna

Leo G. Lenna Sorell, Lenna & Schmidt, LLP135 Engineers RoadHauppauge, NY 11788United States

Goods and services

ClassDescriptionStatusFirst use
035Mail order catalog services featuring dietary supplements, skin care preparations, essential oils for personal use, cosmetics and over the counter pharmaceuticals; On-line retail store services featuring a wide variety of consumer goods of others; On-line retail store services featuring dietary supplements, cosmetics, essential oils for personal use and over-the-counter pharmaceuticalsACTIVEFeb 28, 2018

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Nov 4, 2024EWAFTEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS—
Nov 4, 2024TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Nov 4, 2024ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Nov 4, 2024REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Apr 12, 2024NA85NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED—
Apr 12, 2024C15AREGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.—
Apr 12, 2024APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Oct 16, 2023E815TEAS SECTION 8 & 15 RECEIVED—
Oct 16, 2023REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Oct 16, 2018R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Jul 31, 2018NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Jul 31, 2018PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jul 11, 2018NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jun 20, 2018ALIEASSIGNED TO LIE—
Jun 12, 2018CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jun 12, 2018XAECEXAMINER'S AMENDMENT ENTERED—
Jun 12, 2018GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Jun 12, 2018GNEAEXAMINERS AMENDMENT E-MAILED—
Jun 12, 2018CNEAEXAMINERS AMENDMENT -WRITTEN—
Jun 12, 2018DOCKASSIGNED TO EXAMINER—
Mar 9, 2018NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Mar 6, 2018NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance